Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal to advance cancer treatment

Merck wins FDA priority review for KEYTRUDA bladder cancer combo expansion

If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev

Astellas & Pfizer win FDA priority review for bladder cancer treatment expansion

A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline

Leinco and CellCarta team up to power next-gen proteomics for cancer and targeted therapies

Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research

HCG Cancer Hospital, Borivali hosts ROBOCAN 1.0 to advance robotic cancer surgery adoption

Experts highlighted how robotic-assisted procedures are improving surgical precision, reducing complications, and enabling faster recovery

UICC report flags air pollution as major multi-cancer risk

The long-term exposure to fine particulate matter (PM2.5) increases overall cancer risk by 11%

GE HealthCare expands DeepHealth AI partnership to supercharge breast cancer detection

The move aims to accelerate the development, commercialization, and global rollout of advanced AI-powered mammography tools

Revvity aims to accelerate breakthroughs in cancer research

Revvity is positioning its technologies as a connected engine for discovery

GlycoNex wins Japan nod to launch first human trial of lead program in gastrointestinal cancers

The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy

FDA grants priority review to Daiichi Sankyo & Merck’s lung cancer drug application

The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck